To hear about similar clinical trials, please enter your email below
Trial Title:
Effect of Bupivacaine Liposome Anterior Serratus Deep Block on Chronic Pain After Breast Cancer Surgery: a Randomized Controlled Study
NCT ID:
NCT06427044
Condition:
Breast Cancer Patients With Chronic Pain After Surgery
Conditions: Official terms:
Breast Neoplasms
Chronic Pain
Study type:
Interventional
Study phase:
N/A
Overall status:
Not yet recruiting
Study design:
Allocation:
Randomized
Intervention model:
Parallel Assignment
Primary purpose:
Treatment
Masking:
Single (Outcomes Assessor)
Intervention:
Intervention type:
Drug
Intervention name:
Anterior serratus block group
Description:
Bupivacaine lipid 20mL (20mL 266mg bupivacaine liposomes) was ultrasound-guided for a
single anterior serranus plane block
Arm group label:
Anterior serratus block group
Summary:
This study aims to investigate the effect and influence of liposome bupivacaine anterior
serrat plane block on postoperative chronic pain in breast cancer patients, evaluate the
therapeutic effect of liposome bupivacaine in postoperative chronic pain, and provide a
new method for patients with postoperative chronic pain.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
- Adult patients (aged ≥18 years) who are scheduled to undergo unilateral modified
radical breast cancer surgery
Exclusion Criteria:
-
1. Patients with coagulation dysfunction 2. There are infected patients at the
puncture site 3. For patients allergic to any trial drug 4. Patients who take
painkillers within 48 hours before surgery 5. Severe cardiopulmonary
insufficiency, such as EF< 40%, FEVC < 50% expected; Uncontrolled hypertension;
6. Refuse to perform nerve block puncture 7. Mental disorders, epilepsy
history; 8. Unable to give informed consent or are participating in other
clinical trials.
Gender:
Male
Minimum age:
18 Years
Maximum age:
70 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Address:
City:
Wuhan
Zip:
430000
Country:
China
Contact:
Last name:
LU HUA, 1
Phone:
+8618971287754
Email:
hualuqiang@163.com
Start date:
May 25, 2024
Completion date:
December 30, 2024
Lead sponsor:
Agency:
Lu Hua
Agency class:
Other
Source:
Tongji Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06427044
